Pediatrix Medical Group, Inc.
NYSE•MD
CEO: Mr. Mark S. Ordan
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1995-09-20
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
Contact Information
Market Cap
$1.87B
P/E (TTM)
11.4
16.2
Dividend Yield
--
52W High
$24.99
52W Low
$11.84
52W Range
Rank58Top 74.6%
2.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$492.88M-3.58%
4-Quarter Trend
EPS
$0.85+269.56%
4-Quarter Trend
FCF
$131.95M+54.24%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Net Income Reverses Loss Nine months net income $131.7M versus prior year net loss of $(129.5M); significant profitability turnaround achieved across operations.
Adjusted EBITDA Strong Growth Nine months Adjusted EBITDA reached $209.7M, showing substantial growth from $155.3M last year period due to favorable unit results.
Cash Position Strengthened Cash and equivalents $340.1M as of September 30, 2025, representing a net increase of $110.2M from year-end 2024.
Risk Factors
Revenue Impact From Dispositions Nine months revenue fell $90.5M (6.0%) due to non-same unit activity from practice dispositions completed during 2024.
Regulatory Billing Uncertainty Surprise Billing Legislation (NSA) and potential Medicaid reform changes create uncertainty regarding future payment rates and collections.
Legal Malpractice Exposure Pending legal actions, especially malpractice claims, could result in unfavorable resolutions materially affecting financial condition.
Outlook
Liquidity Supports Operations $450.0M available on Revolving Credit Line; liquidity sufficient to finance working capital and contractual obligations for 12 months.
Strategic Focus Shift Organization renewed focus on hospital-based and maternal-fetal businesses following completion of office practice exits in 2024.
Share Repurchase Authorization $229.1M remains authorized for share repurchases under recent August 2025 board authorization; timing depends on market conditions.
Peer Comparison
Revenue (TTM)
$5.37B
$2.90B
AHCO$2.85B
Gross Margin (Latest Quarter)
GDRX93.2%
NVAX69.5%
CNMD55.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| MD | $1.87B | 11.4 | 19.8% | 29.2% |
| SEM | $1.85B | 16.8 | 6.5% | 18.1% |
| PHVS | $1.71B | -7.3 | -69.1% | 0.3% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.6%
Flat Growth
4Q Net Income CAGR
33.0%
Profitability Improved
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 19, 2026
EPS:$0.53
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 3, 2025|Revenue: $492.88M-3.6%|EPS: $0.85+269.6%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 5, 2025|Revenue: $468.84M-7.0%|EPS: $0.45-124.5%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 6, 2025|Revenue: $458.36M-7.4%|EPS: $0.24+400.0%MeetForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 20, 2025|Revenue: $2.01B+0.9%|EPS: $-1.19-65.3%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 1, 2024|Revenue: $511.16M+0.9%|EPS: $0.23-53.1%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 6, 2024|Revenue: $504.30M+0.7%|EPS: $-1.84-641.2%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 7, 2024|Revenue: $495.10M+0.8%|EPS: $0.05-71.8%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 20, 2024|Revenue: $1.99B+1.1%|EPS: $-0.72-191.1%Miss